Author

Guilan Dong

Observed names: Gui-Lan Dong, Gui‐Lan Dong

Observed institution: Tangshan People's Hospital

OpenAlex ID: A5109480086

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

2022 · Zihua Zou, Puyuan Xing, et al. · BMC Medicine · 47

Circulating tumor cells ( CTCs )/circulating tumor endothelial cells ( CTECs ) and their subtypes in small cell lung cancer: Predictors for response and prognosis

2021 · Hao‐Hua Zhu, Yu‐Tao Liu, et al. · Thoracic Cancer · 30

PDF

Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR -Sensitizing Variants Assessed by Circulating Tumor DNA Testing

2022 · Jiachen Xu, Zheng Liu, et al. · JAMA Oncology · 18

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial

2020 · Yu-Tao Liu, Xue-Zhi Hao, et al. · Cancer Management and Research · 12

PDF

Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study

2022 · Fangfang Shen, Naixin Liang, et al. · Frontiers in Oncology · 10

The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer

2021 · Yu Feng, Yutao Liu, et al. · Cancer Research and Treatment · 10

PDF

ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma

2024 · Tao Xing, Li Li, et al. · BMC Gastroenterology · 8

PDF

CHST7 Methylation Status Related to the Proliferation and Differentiation of Pituitary Adenomas

2022 · Wei Dong, Wenjian Shi, et al. · Cells · 6

PDF

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

2022 · Zihua Zou, Yangchun Gu, et al. · Translational Lung Cancer Research · 5

PDF

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China

2021 · Zihua Zou, Xuezhi Hao, et al. · Thoracic Cancer · 5

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial

2025 · Huiyang Shi, Miaohan Wang, et al. · Thoracic Cancer · 2

PDF

RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs

2025 · Xinjun Tang, Jie Hu, et al. · Cancer Letters · 2

The landscape of MET mutations in Chinese biliary tract cancers.

2020 · Shifeng Xu, Wei Rao, et al. · Journal of Clinical Oncology · 1

Efficacy of Apatinib Combined with Etoposide for Maintenance Therapy in Extensive Stage Small Cell Lung Cancer

2024 · Haili Zhang, Guilan Dong, et al. · Nepalese Journal of Cancer

PDF

Abstract 2739: ARID1A deficiency in HBV related hepatocarcinoma patients is associated with upregulated immune activity

2021 · Tao Xing, Han Wang, et al. · Cancer Research

Analysis of neuroendoscopic or microscopic transsphenoidal approach in the treatment of pituitary tumors of different grades and the measures to reduce the common postoperative complications

2020 · Wei Dong, Cheng Yue, et al. · 中国综合临床

非小細胞肺癌におけるBeclin1とLC3蛋白質の発現と臨床的意義【JST・京大機械翻訳】

2017 · Guilan Dong, Liang Dong, et al. · Shiyong yixue zazhi

Works count: 17

Citation count: 156

H-index: 7

I10-index: 6